Published in N Engl J Med on May 30, 2015
Shave Margins vs. Standard Partial Mastectomy in Breast Cancer Patients (SHAVE2) | NCT02772731
Cavity Shaving in Breast Conserving Surgery for Breast Cancer Patients | NCT02648802
Cavity Shave Margins in Breast Cancer. N Engl J Med (2015) 0.94
Cavity Shave Margins in Breast Cancer. N Engl J Med (2015) 0.91
Cavity Shave Margins in Breast Cancer. N Engl J Med (2015) 0.91
Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol (2016) 0.88
Toolbox to Reduce Lumpectomy Reoperations and Improve Cosmetic Outcome in Breast Cancer Patients: The American Society of Breast Surgeons Consensus Conference. Ann Surg Oncol (2015) 0.81
Early Adoption of the SSO-ASTRO Consensus Guidelines on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Stage I and II Invasive Breast Cancer: Initial Experience from Memorial Sloan Kettering Cancer Center. Ann Surg Oncol (2016) 0.81
Major clinical research advances in gynecologic cancer in 2015. J Gynecol Oncol (2016) 0.81
Reexcision--The Other Breast Cancer Epidemic. N Engl J Med (2015) 0.76
Trends and controversies in multidisciplinary care of the patient with breast cancer. Curr Probl Surg (2016) 0.75
Cavity Shave Margins in Breast Cancer. N Engl J Med (2015) 0.75
Reoperation costs in attempted breast-conserving surgery: a decision analysis. Curr Oncol (2016) 0.75
Appropriate margin for lumpectomy excision of invasive breast cancer. Chin Clin Oncol (2016) 0.75
Cavity Shaving plus Lumpectomy versus Lumpectomy Alone for Patients with Breast Cancer Undergoing Breast-Conserving Surgery: A Systematic Review and Meta-Analysis. PLoS One (2017) 0.75
Low rate of positive margins and re-excision after partial mastectomy in highly selected breast cancer patients: A Chinese single-institution experience. Oncotarget (2017) 0.75
Economic Impact of Routine Cavity Margins Versus Standard Partial Mastectomy in Breast Cancer Patients: Results of a Randomized Controlled Trial. Ann Surg (2017) 0.75
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol (2006) 30.90
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol (2008) 11.03
Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res (2005) 9.70
Gene-expression signatures in breast cancer. N Engl J Med (2009) 9.23
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet (2012) 7.31
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol (2006) 7.24
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol (2007) 7.00
Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med (2009) 6.67
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist (2009) 6.00
Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. J Clin Oncol (2006) 4.66
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA (2011) 4.63
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol (2005) 4.03
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol (2005) 3.83
Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet (2011) 3.60
Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med (2012) 3.38
Concern The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist (2003) 3.36
Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J Natl Cancer Inst (2013) 3.35
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol (2012) 2.98
Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol (2010) 2.91
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol (2007) 2.90
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A (2010) 2.79
NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw (2009) 2.78
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 2.75
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol (2005) 2.69
PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet (2010) 2.66
Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res (2009) 2.49
A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res (2011) 2.26
Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res (2010) 2.26
Breast reconstruction following subcutaneous mastectomy for cancer: a critical appraisal of the nipple-areola complex. Plast Reconstr Surg (2006) 2.26
Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat (2003) 2.26
Marrow assessment for hemophagocytic lymphohistiocytosis demonstrates poor correlation with disease probability. Am J Clin Pathol (2014) 2.20
Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol (2007) 2.19
Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst (2010) 2.16
Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A (2005) 2.16
Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J (2003) 2.11
Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist (2008) 2.10
Interpretative problems and preparative technique influence reliability of intraoperative parathyroid touch imprints. Arch Pathol Lab Med (2003) 2.02
Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer (2003) 2.01
The bimodality index: a criterion for discovering and ranking bimodal signatures from cancer gene expression profiling data. Cancer Inform (2009) 1.98
Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol (2009) 1.93
Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol (2008) 1.92
Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat (2011) 1.90
Challenges translating breast cancer gene signatures into the clinic. Nat Rev Clin Oncol (2011) 1.86
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol (2011) 1.83
Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res (2010) 1.81
Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol (2011) 1.79
Nipple-sparing mastectomy: critical assessment of 51 procedures and implications for selection criteria. Ann Surg Oncol (2008) 1.77
Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1. Pediatr Blood Cancer (2010) 1.76
Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics (2004) 1.76
WT1 mutations in T-ALL. Blood (2009) 1.75
Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol (2010) 1.70
Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J Clin Oncol (2010) 1.63
Reversal of early abnormalities in glucose metabolism in obese youth: results of an intensive lifestyle randomized controlled trial. Diabetes Care (2013) 1.56
Preoperative chemotherapy decreases the need for re-excision of breast cancers between 2 and 4 cm diameter. Ann Surg Oncol (2009) 1.54
Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. J Clin Oncol (2011) 1.54
The cost of breast cancer screening in the Medicare population. JAMA Intern Med (2013) 1.53
Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer (2011) 1.53
Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol (2011) 1.52
Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res (2007) 1.52
A novel pathway that regulates inflammatory disease in the respiratory tract. J Immunol (2007) 1.51
HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Res Treat (2007) 1.47
Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol (2002) 1.47
Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer. Ann Surg Oncol (2011) 1.44
Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res (2010) 1.44
Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Res (2009) 1.43
Classification of breast cancer using genetic algorithms and tissue microarrays. Clin Cancer Res (2006) 1.43
Increasing cytotechnologist workload above 100 slides per day using the BD FocalPoint GS imaging system negatively affects screening performance. Am J Clin Pathol (2012) 1.42
Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood (2010) 1.41
Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers. J Natl Cancer Inst (2011) 1.38
Pathological examination of sentinel lymph node in breast cancer: potential problems and possible solutions. Microsc Res Tech (2002) 1.38
Distinct human papillomavirus type 16 methylomes in cervical cells at different stages of premalignancy. Virology (2009) 1.36
Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer (2010) 1.34
Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis. J Clin Oncol (2008) 1.33
Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics (2011) 1.32
Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: a population-based analysis. Int J Cancer (2007) 1.31
Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer (2004) 1.30
Standardizing slide-based assays in breast cancer: hormone receptors, HER2, and sentinel lymph nodes. Clin Cancer Res (2007) 1.28
Quantitative in situ measurement of estrogen receptor mRNA predicts response to tamoxifen. PLoS One (2012) 1.28
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat (2012) 1.26
Biomarker studies: a call for a comprehensive biomarker study registry. Nat Rev Clin Oncol (2011) 1.26
Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines. Breast Cancer Res Treat (2009) 1.25
Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nat Clin Pract Oncol (2006) 1.24
Beta1,6-branched oligosaccharides are increased in lymph node metastases and predict poor outcome in breast carcinoma. Clin Cancer Res (2005) 1.23
Targeted therapies for cancer 2004. Am J Clin Pathol (2004) 1.23
Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer (2004) 1.22
Access to orthopaedic care for children with medicaid versus private insurance: results of a national survey. J Pediatr Orthop (2006) 1.21
The impact of thymoma histotype on prognosis in a worldwide database. J Thorac Oncol (2015) 1.20
Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Res Treat (2005) 1.20
Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncol (2007) 1.20
Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Res Treat (2010) 1.19
Research issues affecting preoperative systemic therapy for operable breast cancer. J Clin Oncol (2008) 1.18
Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer. Oncologist (2012) 1.18
Higher parity and shorter breastfeeding duration: association with triple-negative phenotype of breast cancer. Cancer (2010) 1.18